secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2021-11-23T23:59:59+00:00
Accession:  0001764013-21-000127
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant enters $36M manufacturing deal with Samsung Biologics for batoclimab
-------------------------------------------------------------------------------

- Minimum purchase commitment estimated at $36M; PSA runs through Dec 31, 2029.
- Immunovant can terminate if it stops all batoclimab development by Jan 2024, paying non-cancellable fees.
- Samsung will manufacture batoclimab drug substance for commercial sale, including process performance qualification batches.
- Agreement builds on Master Services Agreement dated April 30, 2021.
- Either party may terminate for material breach, insolvency, or force majeure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401321000127/0001764013-21-000127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401321000127/imvt-20211117.htm
  HTML page:      https://secwatch.observer/filing/0001764013-21-000127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer